TY - JOUR
T1 - Rhabdomyolysis induced by simvastatin-fluconazole combination
AU - Hazin, Ribhi
AU - Abuzetun, Jamil Y.
AU - Suker, Manar
AU - Porter, Joann
PY - 2008/4
Y1 - 2008/4
N2 - Rhabdomyolysis is a potential adverse consequence of statin therapy. Here, we report a patient with prostate cancer being treated with simvastatin who developed rhabdomyolysis after coadministration with fluconazole. The rhabdomyolysis promptly resolved after discontinuation of fluconazole, suggesting the possible role of drug interaction in the development of rhabdomyolysis with coadministration of the two medications. Both simvastatin and fluconazole were promptly discontinued, and the patient was admitted to the intensive care unit, where vigorous hydration along with urine alkalinization led to resolution of rhabdomyolysis. Since statins are commonly prescribed treatments for individuals with hyperlipidemia, caution is advised in coadministration with azoles such as fluconazole. Although supportive treatment remains the mainstay of therapy for patients with rhabdomyolysis, fatal consequences can arise from hyperkalemia, cardiac arrhythmia, renal failure and disseminated intravascular coagulation.
AB - Rhabdomyolysis is a potential adverse consequence of statin therapy. Here, we report a patient with prostate cancer being treated with simvastatin who developed rhabdomyolysis after coadministration with fluconazole. The rhabdomyolysis promptly resolved after discontinuation of fluconazole, suggesting the possible role of drug interaction in the development of rhabdomyolysis with coadministration of the two medications. Both simvastatin and fluconazole were promptly discontinued, and the patient was admitted to the intensive care unit, where vigorous hydration along with urine alkalinization led to resolution of rhabdomyolysis. Since statins are commonly prescribed treatments for individuals with hyperlipidemia, caution is advised in coadministration with azoles such as fluconazole. Although supportive treatment remains the mainstay of therapy for patients with rhabdomyolysis, fatal consequences can arise from hyperkalemia, cardiac arrhythmia, renal failure and disseminated intravascular coagulation.
UR - http://www.scopus.com/inward/record.url?scp=42349115716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42349115716&partnerID=8YFLogxK
U2 - 10.1016/S0027-9684(15)31280-3
DO - 10.1016/S0027-9684(15)31280-3
M3 - Article
C2 - 18481486
AN - SCOPUS:42349115716
VL - 100
SP - 444
EP - 446
JO - Journal of the National Medical Association
JF - Journal of the National Medical Association
SN - 1943-4693
IS - 4
ER -